Would you consider SGLT2i therapy as a second line agent for treatment of HNF1A-MODY (MODY 3)?

Maagensen H, Høyerup SO, Jensen JS, Thuesen ACB, Forman JL, Thomsen HH, Vestergaard H, Knop FK, Hansen T, Hædersdal S, Støy J, Vilsbøll T. Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care. 2026 Jul 1;49(7):1166-1174. doi: 10.2337/dc25-2572. PMID: 41525167; PMCID: PMC13294792.